Loading...
Market
Region with highest OpenCRISPR adoption by 2027
5
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
Global biotechnology adoption reports and regional health regulatory updates.
Story
ProfluentBio Launches OpenCRISPR: AI-Generated Gene Editor with Modest Impact
Apr 23, 2024, 01:49 AM
ProfluentBio has announced the launch of OpenCRISPR, a groundbreaking open-source AI-generated gene editor. Developed using ProfluentBio's large language models, this tool includes a Cas9-like protein and guide RNA, designed to edit human DNA with modest on-target activity. The initiative, which aims to democratize access to gene editing technology, has the potential to revolutionize biomedicine but is not expected to impact clinical editing in the next 3 years. The sequences and molecules designed by AI have been freely released under the OpenCRISPR initiative, marking a significant milestone in personalized medicine.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia • 25%
Rest of the World • 25%
North America • 25%
Asia • 25%
Europe • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
High adoption by healthcare sector • 25%
High adoption by agricultural sector • 25%
Low adoption by healthcare sector • 25%
Low adoption by agricultural sector • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of the World • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of the World • 25%
Agriculture • 25%
Biomedicine • 25%
Veterinary • 25%
Biotechnology research • 25%
Low (0-10 institutions) • 25%
Moderate (11-30 institutions) • 25%
High (31-50 institutions) • 25%
Very High (over 50 institutions) • 25%
Electronic Health Records • 20%
Medical Imaging • 20%
Genomic Risk Assessments • 20%
Clinical Reasoning • 20%
Other • 20%
North America • 20%
Europe • 20%
Asia-Pacific • 20%
Latin America • 20%
Middle East & Africa • 20%
United States • 25%
European Union • 25%
Japan • 25%
South Korea • 25%